Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 9/20 | 0.53 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 3/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171795 | 1.00 | PTK6 (0.53) | PTK6MAPKAPK5SYKBRAFTTK | |
| SCHEMBL22123619 | 0.92 | PTK6 (0.54) | PTK6MAPKAPK5SYKBRAFTTK | |
| SCHEMBL30193410 | 0.92 | PTK6 (0.54) | PTK6MAPKAPK5SYKBRAFTTK | |
| SCHEMBL30349717 | 0.91 | TTK (0.47) | PTK6MAPKAPK5SYKTTKPTK2 | |
| SCHEMBL22124602 | 0.87 | PTK6 (0.47) | PTK6MAPKAPK5SYKBRAFTTK | |
| SCHEMBL24112094 | 0.86 | PTK6 (0.62) | PTK6MAPKAPK5LCKAURKB | |
| Hydrochloric Acid SCHEMBL22123324 | 0.86 | PTK6 (0.46) | PTK6MAPKAPK5SYKBRAFTTK | |
| SCHEMBL22122923 | 0.86 | PTK6 (0.49) | PTK6MAPKAPK5SYKTTKPTK2 | |
| SCHEMBL30171768 | 0.86 | PTK6 (0.49) | PTK6MAPKAPK5SYKTTKPTK2 | |
| Hydrochloric Acid SCHEMBL22124336 | 0.85 | PTK6 (0.72) | PTK6LCKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885MAPKAPK5 728/4885SYK 992/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885MAPKAPK5 728/4885SYK 992/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2141/4885MAPKAPK5 695/4885SYK 939/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | PTK6 1818/4885MAPKAPK5 516/4885SYK 868/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK6 2211/4885MAPKAPK5 647/4885SYK 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.